Thinking About Buying CPNG Stock MDMP Stock Or AVEO Stock

Motley FoolWhy Coupang Stock Soared TodayWhat happened Shares of Coupang (NYSE: CPNG) rocketed over 40% on Thursday, marking a successful initial public offering (IPO) for the South Korean e-commerce star. So what Coupang's shares closed their first day of trading at $49. Motley FoolWhy FinVolution Stock Skyrocketed TodayShares of FinVolution (NYSE: FINV) have skyrocketed today, up by 30% as of 12:05 p.m. EST, after the company reported fourth-quarter earnings. Loan origination volumes were strong, and FinVolution issued optimistic guidance for 2021. Loan origination volumes increased 24% to 21 billion yuan, topping FinVolution's outlook. TipRanksAcadia Pharmaceuticals: Is Potential Nuplazid Delay A Sign Of Trouble Or An Opportunity? Acadia Pharmaceuticals’ (ACAD) share price was cut almost in half as doubt crept into investors’ minds as to whether or not its lead product, Nuplazid, will be approved for Dementia-Related Psychosis (DRP). The setback came as a shock to the investor community as the product seemed poised for approval before its April 3, 2021 PDUFA date. The FDA requested additional information on the statistical methods used to determine the efficacy of the product in DRP. Naturally, this raises the question of whether additional clinical trials need to be conducted, further delaying the much-needed treatment. Further complicating matters is the virtual silence on the part of the management team at ACAD. Most likely, the team is not intentionally avoiding the analyst community. Instead, they are trying to determine what the FDA wants and how to proceed before commenting. To illustrate how out of the blue the delay is, ACAD offered a glimpse of the market opportunity for Nuplazid in DRP. The team estimates that the addressable market is 10x larger than the current market for Nuplazid in Parkinson's Disease Psychosis (PDP). Nuplazid generated sales of $442 million in 2020, underscoring the potential for a new blockbuster indication for the therapy. Stock Market Reaction The market offered a swift and brutal response to the disappointment by lopping off over $4 billion from ACAD's market cap. However, the market has severely overreacted to the news for a few reasons. First and foremost, the FDA has "identified some deficiencies precluding labeling discussions," according to CEO Steve Davis. The natural question is, what are the deficiencies, and how can they be addressed? The FDA has not identified or provided details of the deficiencies cited, and a final decision has yet to be rendered. So, is this a golden opportunity to accumulate or a sign of more problems to come? Taking a deeper look at this unique situation, Nuplazid is an approved product with a growing sales base. The FDA did issue a Black Box warning that Elderly patients with PDP treated with antipsychotic drugs are at an increased risk of death.